Skip to main content
Top

2010 | OriginalPaper | Hoofdstuk

Wat zijn de oorzaken van hypertriglyceridemie? Moet een hypertriglyceridemie worden behandeld en zo ja, met welk medicament?

Auteur : prof. dr. A. F. H. Stalenhoef

Gepubliceerd in: De meest gestelde vragen over: cholesterol

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Hypertriglyceridemie berust op een verhoogde concentratie van triglyceriderijke very-low density lipoproteïnen (VLDL) in het bloed, die door de lever worden geproduceerd en in de circulatie worden uitgescheiden. Bij sterke triglycerideverhoging (> 8 mmol/l) zijn tevens chylomicronen aanwezig, relatief grote partikels gevormd in de darm, die het vet uit de voeding transporteren. Het serum heeft daarbij een sterk troebel tot melkachtig aspect. Chylomicronen verschijnen na een maaltijd in de circulatie, maar zijn in nuchtere toestand na een nacht vasten normaliter afwezig door hun korte halfwaardetijd.
Literatuur
1.
go back to reference Stalenhoef AFH. Serumtriglyceriden als risicofactor voor atherosclerose. Ned Tijdschr Geneeskd 1999; 143: 284–87.PubMed Stalenhoef AFH. Serumtriglyceriden als risicofactor voor atherosclerose. Ned Tijdschr Geneeskd 1999; 143: 284–87.PubMed
2.
go back to reference Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213–29.PubMedCrossRef Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213–29.PubMedCrossRef
3.
go back to reference Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115: 450–58.PubMedCrossRef Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115: 450–58.PubMedCrossRef
4.
go back to reference Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299–308.PubMedCrossRef Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299–308.PubMedCrossRef
5.
go back to reference Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298: 309–16.PubMedCrossRef Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298: 309–16.PubMedCrossRef
6.
go back to reference Stalenhoef AF, Graaf J de. Association of fasting and non-fasting serum triglycerides with cardiovascular disease and role of remnant-like lipoproteins and small dense LDL. Curr Opin Lipodol 2008; 19 (4): 355–61.CrossRef Stalenhoef AF, Graaf J de. Association of fasting and non-fasting serum triglycerides with cardiovascular disease and role of remnant-like lipoproteins and small dense LDL. Curr Opin Lipodol 2008; 19 (4): 355–61.CrossRef
7.
go back to reference Stalenhoef AFH, Graaf J de, Wittekoek ME, Bredie SJH, Demacker PNM, Kastelein JJP. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertrygliceridemia. Atherosclerosis 2000; 153: 129–38.PubMedCrossRef Stalenhoef AFH, Graaf J de, Wittekoek ME, Bredie SJH, Demacker PNM, Kastelein JJP. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertrygliceridemia. Atherosclerosis 2000; 153: 129–38.PubMedCrossRef
8.
go back to reference Bloomfield Rubins H, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of HDL-cholesterol. N Engl J Med 1999; 341: 410–18.CrossRef Bloomfield Rubins H, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of HDL-cholesterol. N Engl J Med 1999; 341: 410–18.CrossRef
9.
go back to reference The BIP Study Group. Secundary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary artery disease – the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21–27.CrossRef The BIP Study Group. Secundary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary artery disease – the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21–27.CrossRef
10.
go back to reference The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005; 366: 1849–61.CrossRef The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005; 366: 1849–61.CrossRef
11.
go back to reference Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease – a pooled meta-analysis of longterm randomized placebo-controlled clinical trials. Am Heart J 2007; 154: 943–53.PubMedCrossRef Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease – a pooled meta-analysis of longterm randomized placebo-controlled clinical trials. Am Heart J 2007; 154: 943–53.PubMedCrossRef
Metagegevens
Titel
Wat zijn de oorzaken van hypertriglyceridemie? Moet een hypertriglyceridemie worden behandeld en zo ja, met welk medicament?
Auteur
prof. dr. A. F. H. Stalenhoef
Copyright
2010
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-313-7508-0_3